We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
HealthEquity (HQY) Q1 Earnings Beat Estimates, FY22 View Up
Read MoreHide Full Article
HealthEquity, Inc. (HQY - Free Report) reported adjusted earnings per share (EPS) of 38 cents for first-quarter fiscal 2022, which beat the Zacks Consensus Estimate by 22.6%. However, the bottom line fell 11.6% on a year-over-year basis.
GAAP loss per share in the fiscal first quarter was 3 cents against the year-ago period’s EPS of 3 cents.
Revenues in Detail
For the fiscal first quarter, the company generated revenues of $184.2 million, outpacing the Zacks Consensus Estimate by 0.6%. However, the top line dipped 3.1% from the prior-year quarter.
HSA Details
As of Apr 30, 2021, the total number of Health Savings Accounts (HSA) for which HealthEquity served as a non-bank custodian (HSA members) came in at 5.8 million, up 8.7% year over year.
Additionally, total Active HSA assets were $15 billion at the end of the reported quarter, up 30.5% year over year. Total Accounts as of Apr 30, 2021 were 12.8 million, up 0.9% year over year. This uptick included total HSAs as well as 6.9 million Consumer Direct Benefits or CDB.
Revenue Sources
HealthEquity derives revenues from three sources, namely Service revenues, Custodial revenues and Interchange revenues.
Service revenues totaled $102.5 million, down 7.9% year over year, primarily due to a significant (more than 60%) decrease in active commuter accounts. However, the segment was benefited by growth in HSAs and other CDBs.
Custodial revenues totaled $46.9 million, up by 0.2% from the year-ago period. Per management, growth in average HSA cash with yield and a significant uptick in average HSA investments with yield more than offset a 33-basis point (bps) fall in the annualized yield on HSA cash.
Interchange revenues totaled $34.7 million, up 8.9% year over year. The revenue outperformance was primarily led by a rebound in spend across HealthEquity’s platforms in the reported quarter and growth in average total accounts.
HealthEquity, Inc. Price, Consensus and EPS Surprise
In the quarter under review, HealthEquity’s gross profit fell 4.6% to $103.1 million. Gross margin contracted 90 bps to 55.9%.
Meanwhile, sales and marketing expenses rose 22.9% to $14.1 million year over year. Technology and development expenses climbed 14.1% year over year to $35.5 million whereas general and administrative expenses grew 8.9% year over year to $20.7 million. Adjusted operating expenses of $70.2 million increased 14.2% year over year.
Adjusted operating profit totaled $32.9 million, declining 29.4% from the prior-year quarter. Further, adjusted operating margin in the quarter contracted a huge 665 bps to 17.8%.
Financial Position
The company exited first-quarter fiscal 2022 with cash and cash equivalents of $736.8 million compared with $328.8 million at the end of fiscal 2021. Total debt in the fiscal first quarter (net of issuance costs) is $972.3 million compared with $986.7 million at the end of fiscal 2021.
Net cash flow from operating activities in the quarter totaled $30.9 million, up from $15 million in the year-ago period.
FY22 Guidance
HealthEquity, on the basis of its fiscal first quarter performance, raised its earlier provided financial outlook for full fiscal.
For fiscal 2022, revenues are now projected in the range of $755 million-$765 million (up from the earlier projection in the band of $750 million-$760 million). The Zacks Consensus Estimate for the same is currently pegged at $756.2 million.
Adjusted EPS is expected within $1.45-$1.50, up from the previous estimate of $1.37-$1.42. The Zacks Consensus Estimate for the same currently stands at $1.40.
Our Take
HealthEquity exited first-quarter fiscal 2022 with better-than-expected results. The top line benefited from the robust contributions of Custodial and Interchange revenues. Solid growth in HSAs also drove the top line. In addition to HSA, the company offers health reimbursement arrangement to regional employers.
HealthEquity continued to gain from the acquisition of WageWorks, which was completed in August 2019. The company raising its fiscal 2022 financial outlook despite pandemic-led business challenges buoys optimism on the stock.
However, the company’s year-over-year fall in both adjusted EPS and the overall top line is concerning. Weakness in Service revenues is also disappointing. Contraction of both margins does not bode well either. The company also faces stiff competition in the Medical Services market, thus raising apprehensions.
Zacks Rank and Key Picks
HealthEquity currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Apollo Medical Holdings, Inc. , AMN Healthcare Services Inc. (AMN - Free Report) and Veeva Systems Inc. (VEEV - Free Report) .
AMN Healthcare, a Zacks Rank #1 company, reported first-quarter 2021 adjusted EPS of $1.70, beating the Zacks Consensus Estimate by 25%. Revenues of $885.9 million outpaced the consensus mark by 9.2%.
Veeva Systems reported first-quarter 2021 adjusted EPS of 91 cents, surpassing the Zacks Consensus Estimate by 16.7%. Net revenues of $433.6 million outpaced the consensus estimate by 5.9%. It currently carries a Zacks Rank #2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Bigstock
HealthEquity (HQY) Q1 Earnings Beat Estimates, FY22 View Up
HealthEquity, Inc. (HQY - Free Report) reported adjusted earnings per share (EPS) of 38 cents for first-quarter fiscal 2022, which beat the Zacks Consensus Estimate by 22.6%. However, the bottom line fell 11.6% on a year-over-year basis.
GAAP loss per share in the fiscal first quarter was 3 cents against the year-ago period’s EPS of 3 cents.
Revenues in Detail
For the fiscal first quarter, the company generated revenues of $184.2 million, outpacing the Zacks Consensus Estimate by 0.6%. However, the top line dipped 3.1% from the prior-year quarter.
HSA Details
As of Apr 30, 2021, the total number of Health Savings Accounts (HSA) for which HealthEquity served as a non-bank custodian (HSA members) came in at 5.8 million, up 8.7% year over year.
Additionally, total Active HSA assets were $15 billion at the end of the reported quarter, up 30.5% year over year. Total Accounts as of Apr 30, 2021 were 12.8 million, up 0.9% year over year. This uptick included total HSAs as well as 6.9 million Consumer Direct Benefits or CDB.
Revenue Sources
HealthEquity derives revenues from three sources, namely Service revenues, Custodial revenues and Interchange revenues.
Service revenues totaled $102.5 million, down 7.9% year over year, primarily due to a significant (more than 60%) decrease in active commuter accounts. However, the segment was benefited by growth in HSAs and other CDBs.
Custodial revenues totaled $46.9 million, up by 0.2% from the year-ago period. Per management, growth in average HSA cash with yield and a significant uptick in average HSA investments with yield more than offset a 33-basis point (bps) fall in the annualized yield on HSA cash.
Interchange revenues totaled $34.7 million, up 8.9% year over year. The revenue outperformance was primarily led by a rebound in spend across HealthEquity’s platforms in the reported quarter and growth in average total accounts.
HealthEquity, Inc. Price, Consensus and EPS Surprise
HealthEquity, Inc. price-consensus-eps-surprise-chart | HealthEquity, Inc. Quote
Margin Details
In the quarter under review, HealthEquity’s gross profit fell 4.6% to $103.1 million. Gross margin contracted 90 bps to 55.9%.
Meanwhile, sales and marketing expenses rose 22.9% to $14.1 million year over year. Technology and development expenses climbed 14.1% year over year to $35.5 million whereas general and administrative expenses grew 8.9% year over year to $20.7 million. Adjusted operating expenses of $70.2 million increased 14.2% year over year.
Adjusted operating profit totaled $32.9 million, declining 29.4% from the prior-year quarter. Further, adjusted operating margin in the quarter contracted a huge 665 bps to 17.8%.
Financial Position
The company exited first-quarter fiscal 2022 with cash and cash equivalents of $736.8 million compared with $328.8 million at the end of fiscal 2021. Total debt in the fiscal first quarter (net of issuance costs) is $972.3 million compared with $986.7 million at the end of fiscal 2021.
Net cash flow from operating activities in the quarter totaled $30.9 million, up from $15 million in the year-ago period.
FY22 Guidance
HealthEquity, on the basis of its fiscal first quarter performance, raised its earlier provided financial outlook for full fiscal.
For fiscal 2022, revenues are now projected in the range of $755 million-$765 million (up from the earlier projection in the band of $750 million-$760 million). The Zacks Consensus Estimate for the same is currently pegged at $756.2 million.
Adjusted EPS is expected within $1.45-$1.50, up from the previous estimate of $1.37-$1.42. The Zacks Consensus Estimate for the same currently stands at $1.40.
Our Take
HealthEquity exited first-quarter fiscal 2022 with better-than-expected results. The top line benefited from the robust contributions of Custodial and Interchange revenues. Solid growth in HSAs also drove the top line. In addition to HSA, the company offers health reimbursement arrangement to regional employers.
HealthEquity continued to gain from the acquisition of WageWorks, which was completed in August 2019. The company raising its fiscal 2022 financial outlook despite pandemic-led business challenges buoys optimism on the stock.
However, the company’s year-over-year fall in both adjusted EPS and the overall top line is concerning. Weakness in Service revenues is also disappointing. Contraction of both margins does not bode well either. The company also faces stiff competition in the Medical Services market, thus raising apprehensions.
Zacks Rank and Key Picks
HealthEquity currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Apollo Medical Holdings, Inc. , AMN Healthcare Services Inc. (AMN - Free Report) and Veeva Systems Inc. (VEEV - Free Report) .
Apollo Medical Holdings reported first-quarter 2021 adjusted EPS of 30 cents, beating the Zacks Consensus Estimate by 36.4%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AMN Healthcare, a Zacks Rank #1 company, reported first-quarter 2021 adjusted EPS of $1.70, beating the Zacks Consensus Estimate by 25%. Revenues of $885.9 million outpaced the consensus mark by 9.2%.
Veeva Systems reported first-quarter 2021 adjusted EPS of 91 cents, surpassing the Zacks Consensus Estimate by 16.7%. Net revenues of $433.6 million outpaced the consensus estimate by 5.9%. It currently carries a Zacks Rank #2.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>